American Joint Committee on Cancer Prognostic Factors Consensus Conference

Yarbro, John W.; Page, David L.; Fielding, L P; Partridge, Edward E.; Murphy, Gerald P.

doi:10.1002/(sici)1097-0142(19991201)86:11<2436::aid-cncr35>3.0.co;2-#

Cited by 155 publications

(71 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A metastasis in an internal mammary sentinel node is detected at an early stage and carries a prognosis that is probably not much worse than is true for an involved sentinel node in the axilla, which is classified as N1. Another subject of debate is the clinical relevance of micrometastasis, especially if detected by techniques like step sectioning or immunohistochemical staining (Yarbro et al, 1999). Six of 17 patients (35%) had an internal mammary node metastasis smaller than 2 mm.…”

Section: Discussionmentioning

confidence: 99%

Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients

et al. 2002

View full text Add to dashboard Cite

The purpose of this study was to evaluate the occurrence of lymphatic drainage to non-axillary sentinel nodes and to determine the implications of this phenomenon. A total of 549 breast cancer patients underwent lymphoscintigraphy after intratumoural injection of 99m Tc-nanocolloid. The sentinel node was intraoperatively identified with the aid of intratumoural administered patent blue dye and a gamma-ray detection probe. Histopathological examination of sentinel nodes included step-sectioning at six levels and immunohistochemical staining. A sentinel node outside level I or II of the axilla was found in 149 patients (27%): internal mammary sentinel nodes in 86 patients, other non-axillary sentinel nodes in 44 and both internal mammary and other non-axillary sentinel nodes in nineteen patients. The intra-operative identification rate was 80%. Internal mammary metastases were found in seventeen patients and metastases in other non-axillary sentinel nodes in ten patients. Staging improved in 13% of patients with non-axillary sentinel lymph nodes and their treatment strategy was changed in 17%. A small proportion of clinically node negative breast cancer patients can be staged more precisely by biopsy of sentinel nodes outside level I and II of the axilla, resulting in additional decision criteria for postoperative regional or systemic therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients

et al. 2002

View full text Add to dashboard Cite

show abstract

“…8,9 Taken together, these important considerations converge into a strong need for reliable prognostic and predictive biomarkers that are able, with high specificity and sensitivity, to correctly identify patients who would or would not benefit from specific therapeutic intervention, as well as to predict the response of their tumor to a specific line of therapy. [8][9][10][11] This review summarizes the use of telomere length or its proxies, such as telomere content, as potential prognostic markers in solid tumors, a possibility that has been raised in the last decade by a number of investigators. [12][13][14][15][16][17][18][19][20][21][22][23][24] A corresponding comprehensive discussion of these promising developments has not yet been offered, in spite of the growing body of knowledge.…”

mentioning

confidence: 99%

“…These include providing a basis for choice of initial treatment, prediction of survival, stratification of patients into clinical trials, prediction and monitoring of response to therapy, accurate communication among health care providers and uniform reporting of outcomes. [8][9][10][11]27 The TumorNodes-Metastasis (TNM) staging system has been used since the 1950s, and meets most of the criteria outlined earlier. 10,11,27 Using this system, the patient is stratified into a specific stage.…”

mentioning

confidence: 99%

Telomeres: Prognostic markers for solid tumors

Bisoffi

Heaphy

Griffith

2006

Intl Journal of Cancer

101

View full text Add to dashboard Cite

Solid tumors continue to affect millions of people worldwide. Increasingly sophisticated diagnostic tools contribute to the high incidence rates for some tumor types, and treatment options continue to expand. However, the progression of solid tumors represents a challenge for the appropriate treatment of individual patients because of the relative inaccuracy of current prognostic markers, including the widely used Tumor-Nodes-Metastasis (TNM) staging system, to predict the course of disease. As a result, both over-and undertreatment are clinical realities in the management of patients diagnosed with solid tumors. Therefore, populationbased screening programs that increase the overall cancer incidence rates are controversial, as they may do little to improve the patient's quality of life. Consequently, there is a strong need to develop novel and independent markers of prognosis. In this context, we review the use of telomeres as prognostic markers for solid tumors, including cancers from lung, breast, prostate, colon, brain and head and neck. Telomeric sequences, the repetitive DNA at the end of human chromosomes, are mediators of genomic stability and can undergo length alterations during tumor initiation and progression. In a number of studies reviewed here, these alterations, measured as telomere attrition and elongation, have been shown either to be associated with clinical markers of disease progression or to be independent markers of cancer prognosis. We conclude from these studies that careful assessment of telomere length or its proxies, such as telomere DNA content, will be part of novel risk assessment and prognostic modalities for patients with solid tumors. ' 2006 Wiley-Liss, Inc.

show abstract

“…La estimación de estas probabilidades se basa en la etapa de la enfermedad (TNM), características patológicas de la neoplasia y eficacia del tratamiento [12][13][14] . De este modo; tumores pequeños (T1: Tamaño tumoral menor o igual a 2 centíme-tros), sin compromiso de los nodos linfáticos (N0), y en ausencia de enfermedad metastásica (M0) tienen un mejor pronóstico en comparación con tumores en etapas más avanzadas.…”

Section: Discussionunclassified

Evaluación de un modelo computacional para la indicación de quimioterapia en cáncer de mama

Galindo

et al. 2007

Rev Chil Cir

View full text Add to dashboard Cite

American Joint Committee on Cancer Prognostic Factors Consensus Conference

Cited by 155 publications

References 35 publications

Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients

Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients

Telomeres: Prognostic markers for solid tumors

Evaluación de un modelo computacional para la indicación de quimioterapia en cáncer de mama

Contact Info

Product

Resources

About